Filing Flows › Orchestra BioMed Holdings (OBIO) › Q1 2026 › vs Q4 2025
Orchestra BioMed Holdings (OBIO) Q1 2026 vs Q4 2025 (quarter over quarter)
Orchestra BioMed Holdings's revenue fell $30.8M (-100%) from $30.9M in Q4 2025 to $110K in Q1 2026.
Orchestra BioMed Holdings, Q1 2026: revenue $110K (-87% year over year), net loss $20.7M, operating cash flow −$22.2M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $110K | $30.9M | −$30.8M | -100% |
| Other income, net | $1.4M | −$509K | $1.9M | — |
| Net loss | $20.7M | −$6.2M | $26.9M | — |
| Costs & expenses | $22.2M | $30.9M | −$8.7M | -28% |
| Operating costs | $22.2M | $24.2M | −$2.0M | -8% |
| Cost of revenue | $32K | $51K | −$19K | -37% |
| Research & development | $15.8M | $16.8M | −$1.0M | -6% |
| SG&A | $6.4M | $7.3M | −$916K | -13% |
| Operating cash sources | $25.1M | $5.1M | $20.0M | +392% |
| Depreciation & amortization | $90K | $82K | $8K | +10% |
| Share-based compensation | $2.9M | $2.8M | $101K | +4% |
| Cash used in operations | $22.2M | $2.3M | $19.9M | +877% |
| Net loss absorbed | $20.7M | −$6.2M | $26.9M | — |
| Working capital & other | $4.4M | $11.3M | −$6.9M | -61% |
Questions
How much did Orchestra BioMed Holdings's revenue grow quarter over quarter in Q1 2026?
Orchestra BioMed Holdings's revenue fell $30.8M (-100%) from $30.9M in Q4 2025 to $110K in Q1 2026.